BioSpace News Archive

Trialjectory (“the Company’’) announced today new data showing that triple-negative breast cancer (TNBC) patients are more likely to seek clinical trial options for their disease compared to other subtypes and, in advanced disease setting, sooner and prior to treatment compared to patients with non-triple-negative breast cancer.

ANEW MEDICAL, INC. (“ANEW” or “the Company”) (OTCPK:LEAS), a medical technology holding company announced that it has acquired an exclusive worldwide license from Universitat Autonomous de Barcelona (UAB) and affiliated institutions to a platform technology for discovery and development of cell and gene therapy products based on a proprietary human protein and gene called α-Klotho.

Inizio, a strategic partner for companies in health and life sciences, has today announced the acquisition of Evolution Road, a digital innovation company in life science omnichannel, digital marketing and digital health strategy.

American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) (the “Company” or “Aires”) announces that, further to its previous press releases of May 9, 2022, June 23, 2022, August 2, 2022, August 26, 2022, September 21, 2022, October 21, 2022 and November 3, 2022,

hC Bioscience, Inc., a pioneer in the development of tRNA-based therapeutics, appointed Martin Maier, Ph.D., to its Scientific Advisory Board. Dr. Maier’s background will bring, among other contributions, an expertise in nucleic acid chemistry and delivery, and the development of nucleic acid therapeutics.

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that it has initiated its 7-day dose-ranging, toxicology study, using rats, for its lead molecule MB-204. This is a vital step in preparation to initiate FDA Phase I human clinical trials.

The global neurovascular devices market size was exhibited at USD 2.94 billion in 2022 and is expected to hold around USD 4.52 billion by 2030 growing at a CAGR of 5.7% from 2022 to 2030.

The global life science reagents market size was exhibited at USD 88.22 billion in 2022 and is expected to hold around USD 88.22 billion by 2030 growing at a CAGR of 8.3% from 2022 to 2030.

The global genetic testing market size was exhibited at USD 8.52 billion in 2022 and is expected to hold around USD 15.80 billion by 2030 growing at a CAGR of 5.25% from 2022 to 2030

The global drug and gene delivery devices market size was exhibited at USD 438.36 billion in 2022 and is expected to hold around USD 815.06 billion by 2030 growing at a CAGR of 7.2% from 2022 to 2030.